85 related articles for article (PubMed ID: 28304277)
21. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
22. SF3B1 association with chromatin determines splicing outcomes.
Kfir N; Lev-Maor G; Glaich O; Alajem A; Datta A; Sze SK; Meshorer E; Ast G
Cell Rep; 2015 Apr; 11(4):618-29. PubMed ID: 25892229
[TBL] [Abstract][Full Text] [Related]
23. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
24. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S; Haferlach T; Weissmann S; Meggendorfer M; Eder C; Nadarajah N; Alpermann T; Kohlmann A; Kern W; Haferlach C; Schnittger S
Haematologica; 2015 Apr; 100(4):e125-7. PubMed ID: 25527566
[No Abstract] [Full Text] [Related]
25. [Splicing factor mutations in myelodysplastic syndromes].
Shiozawa Y
Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
[TBL] [Abstract][Full Text] [Related]
26. The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site.
de Graaf K; Czajkowska H; Rottmann S; Packman LC; Lilischkis R; Lüscher B; Becker W
BMC Biochem; 2006 Mar; 7():7. PubMed ID: 16512921
[TBL] [Abstract][Full Text] [Related]
27. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A; Abdel-Wahab O
Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
[TBL] [Abstract][Full Text] [Related]
28. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
[TBL] [Abstract][Full Text] [Related]
29. Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.
Hepburn LA; McHugh A; Fernandes K; Boag G; Proby CM; Leigh IM; Saville MK
Oncotarget; 2018 May; 9(33):23029-23046. PubMed ID: 29796170
[TBL] [Abstract][Full Text] [Related]
30. Identification of four genes required for mammalian blastocyst formation.
Maserati M; Dai X; Walentuk M; Mager J
Zygote; 2014 Aug; 22(3):331-9. PubMed ID: 23211737
[TBL] [Abstract][Full Text] [Related]
31. Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma.
Cutcutache I; Wu AY; Suzuki Y; McPherson JR; Lei Z; Deng N; Zhang S; Wong WK; Soo KC; Chan WH; Ooi LL; Welsch R; Tan P; Rozen SG
Gastric Cancer; 2016 Apr; 19(2):453-465. PubMed ID: 26205786
[TBL] [Abstract][Full Text] [Related]
32. SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.
Küsters-Vandevelde HV; Creytens D; van Engen-van Grunsven AC; Jeunink M; Winnepenninckx V; Groenen PJ; Küsters B; Wesseling P; Blokx WA; Prinsen CF
Acta Neuropathol Commun; 2016 Jan; 4():5. PubMed ID: 26769193
[TBL] [Abstract][Full Text] [Related]
33. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
[TBL] [Abstract][Full Text] [Related]
34. A chemical genetics approach for the functional assessment of novel cancer genes.
Zhou Q; Derti A; Ruddy D; Rakiec D; Kao I; Lira M; Gibaja V; Chan H; Yang Y; Min J; Schlabach MR; Stegmeier F
Cancer Res; 2015 May; 75(10):1949-58. PubMed ID: 25788694
[TBL] [Abstract][Full Text] [Related]
35. Genital mucosal melanoma with somatic SF3B1 R625C mutation.
Oiso N; Sakai K; Yanagihara S; Nishio K; Kawada A
Eur J Dermatol; 2018 Jun; 28(3):414-415. PubMed ID: 29624176
[No Abstract] [Full Text] [Related]
36. Myelodysplastic Syndrome Updated.
Hasserjian RP
Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
[TBL] [Abstract][Full Text] [Related]
37. New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
Filip AA
Leuk Lymphoma; 2013 Sep; 54(9):1876-81. PubMed ID: 23343182
[TBL] [Abstract][Full Text] [Related]
38. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
39. Microprocessor-dependent processing of splice site overlapping microRNA exons does not result in changes in alternative splicing.
Pianigiani G; Licastro D; Fortugno P; Castiglia D; Petrovic I; Pagani F
RNA; 2018 Sep; 24(9):1158-1171. PubMed ID: 29895677
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
